Pan-cancer immunogenomics and structure-guided repurposing identify N-Acetyl-L-carnosine as a PAR2 binding modulator

Puntos clave

• N-acetyl-L-carnosine shows promise as a PAR2 binding modulator, indicating its potential utility in cancer therapies.
• The study highlights the integration of immunogenomics with structure-guided repurposing to discover new therapeutic agents.
• This analysis emphasizes the relevance of binding modulators in cancer treatment strategies, aiming to enhance immunotherapy efficacy.
• Potential applications span multiple cancer types, inviting further investigation into N-acetyl-L-carnosine's benefits and mechanisms.